Form 4: Neurogene Inc. Executive Cobb Stuart Reports Acquisition of Restricted Stock Units and Stock Options

Neurogene Inc.'s Chief Scientific Officer, Stuart Cobb, reports the acquisition of restricted stock units and stock options in a recent SEC filing.

Summary

• On March 26, 2025, Stuart Cobb, the Chief Scientific Officer of Neurogene Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of 7,200 restricted stock units and options to purchase 42,900 shares of Neurogene's common stock.
• The restricted stock units vest in three equal annual installments starting on the first anniversary of the grant date.
• The stock options vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal monthly installments over the following three years.
• The exercise price for the stock options is $16.14.
• Following the reported transactions, Cobb beneficially owns 27,591 shares of common stock and options to purchase 42,900 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance. The vesting schedules suggest a long-term commitment from the executive.

Positives

• The grant of restricted stock units and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company's success.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The grant of equity-based compensation can motivate executives to improve company performance, benefiting shareholders.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Neurogene Inc., Stuart Cobb, Stock Options, Restricted Stock Units, Beneficial Ownership, SEC Filing, NGNE